亨迪药业 (301211)
Hubei Biocause Heilen Pharmaceutical Co., Ltd.
K-Line Chart
No K-line data available
Company NameHubei Hengdi Pharmaceutical Co., Ltd.
Listing Date2021-12-22
Issue Price25.8RMB
Registered Capital4176010k RMB
Legal RepresentativeCheng Zhigang
Registered AddressNo. 122 Yangwan Road, Duodao District, Jingmen City, Hubei Province
IndustryChemical Pharmaceuticals
Main BusinessResearch, development, production, and sales of chemical active pharmaceutical ingredients (APIs) and finished dosage forms.
Company ProfileHubei Hengdi Pharmaceutical Co., Ltd. is a drafter and formulator of multiple industry standards and specifications in China's API sector. It is one of the few API manufacturers in China that has simultaneously obtained certifications from China GMP, U.S. FDA, and EU CEP.
Its wholly-owned or controlled subsidiaries include Hubei Baike Gelai, Wuhan Baike Pharmaceuticals, Shandong Zaozhuang Baike, Hubei Baike Saponin, Hubei Baike Commerce & Trade, Hubei Baike Chemical, among others.
At its headquarters in Jingmen, Hubei, it operates several production lines for APIs, infusions, granules, capsules, etc. Main APIs include: Torasemide, Dexibuprofen, Ibuprofen Lysinate, Balsalazide Sodium, Oxaprozin, Fludarabine Phosphate, Granisetron Hydrochloride, Milrinone, Flumazenil, Barnidipine Hydrochloride, Mecamylamine Hydrochloride, Cladribine, Mitoxantrone Hydrochloride, Dolasetron Mesylate, Tropisetron Hydrochloride, Homatropine Methylbromide, Brotizolam, etc.
Stock Details
1. Key Indicators
- Total Shares(W): 41760.00
- Circulating A-Shares(W): 41760.00
- Earnings Per Share(RMB): 0.0500
- Net Assets Per Share(RMB): 5.4102
- Operating Revenue(W RMB): 31889.67
- Total Profit(W RMB): 2311.68
- Net Profit Attributable to Parent(W RMB): 2093.34
- Net Profit Growth Rate(%): -71.96
- Weighted Return on Equity(%): 0.9200
- Operating Cash Flow Per Share(RMB): 0.0450
- Undistributed Profit Per Share(RMB): 0.3747
- Capital Reserve Per Share(RMB): 3.8959
2. Main Business
The main business covers:
- Research, production, and sales of chemical APIs (including intermediates) and preparation products.
3. Company Basic Information
- Company Name: Hubei Biocause Heilen Pharmaceutical Co., Ltd.
- Listing Date: 2021-12-22
- Industry: Pharmaceutical Manufacturing
- Address: No. 122 Yangwan Road, Duodao District, Jingmen High-tech Zone, Hubei Province
- Website: www.biocause.com
- Company Profile: On June 8, 2020, Daxin Certified Public Accountants issued the audit report for the company's overall restructuring. On June 9, 2020, Zhongjing Minxin Appraisal issued the evaluation report. On June 10, 2020, the temporary shareholders' meeting unanimously agreed to restructure the company into a joint-stock company. The company was officially established as a joint-stock company on June 28, 2020.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shanghai Yongdasheng Business Consulting Co., Ltd. | General Legal Person | 15973.20 | 38.25 |
| 2 | Jingmen Ningkang Enterprise Management Center (Limited Partnership) | General Legal Person | 2349.00 | 5.63 |
| 3 | Jingmen Beikang Enterprise Management Center (Limited Partnership) | General Legal Person | 783.00 | 1.88 |
| 4 | Orient Quantitative Multi-Strategy Hybrid Securities Investment Fund Class A | Fund | 1.16 | 0.00 |
5. Concept Sectors
- Vitamin
- CXO Concept
- Hepatitis Concept
- Margin Trading & Securities Lending
- Below IPO Price
- Intended Reduction
- Small Cap Growth Enterprise Board
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information